Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Benefiber ‘Helps Maintain Regularity’ Claim Fails NAD Review; Decision Appealed

This article was originally published in The Tan Sheet

Executive Summary

Novartis Health disagrees with the National Advertising Division decision that the Benefiber express claim “helps maintain regulatory” is not supported by research and will appeal the decision. NAD reviewed the claim made in a challenge by Metamucil fiber supplement marketer P&G.

You may also be interested in...

GSK's Benefiber Constipation-Relief Claim Supported In Review Following P&G Challenge

GSK supported claim Benefiber Healthy Balance supplement "helps relieve occasional constipation and abdominal discomfort without causing diarrhea" in challenge by Metamucil marketer P&G. Dispute decided in industry self-regulation form focused on PHGG's mechanism of action in reliving constipation.

Neurocet Cliff's Notes Fail NAD Test For 'Stronger Than Morphine' Claim

NAD says direct advertising claims for the Neurocet supplement rely on insufficient or ill-fitted research – including summaries – and marketer National Media Group should discontinue numerous statements challenged by the Council for Responsible Nutrition.

In Comments And In Person, Pharmacist Groups Remind US FDA They'll Provide ACNU Help

Pharmacist groups’ representatives, in meeting with FDA officials, reiterate argument for greater role in access to OTCs through “additional conditions for nonprescription use.” Group not at meeting, American Society of Health-System Pharmacists, suggests “intermediate approach to nonprescription status.”


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts